株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

全身性エリテマトーデス(SLE)- 疫学予測 2028年

Systemic Lupus Erythematosus (SLE) - Epidemiology Forecast - 2028

発行 DelveInsight Business Research LLP 商品コード 535000
出版日 ページ情報 英文 92 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=109.81円で換算しております。
Back to Top
全身性エリテマトーデス(SLE)- 疫学予測 2028年 Systemic Lupus Erythematosus (SLE) - Epidemiology Forecast - 2028
出版日: 2019年11月01日 ページ情報: 英文 92 Pages
概要

主要7カ国(米国、英国、ドイツ、フランス、イタリア、スペイン、日本)における全身性エリテマトーデス(SLE)の2017年の罹患数は981万9,080人と推計されています。

当レポートでは、主要7カ国(米国、英国、ドイツ、フランス、イタリア、スペイン、日本)における全身性エリテマトーデス(SLE)市場を調査し、疾病の概要、疫学的予測、性別・年齢・病型別の有病数の推移と予測、アンメットニーズ、市場の成長要因および障壁などを包括的にまとめています。

目次

第1章 重要洞察

第2章 全身性エリテマトーデス(SLE):患者概要

  • 患者の分布(実数値)
  • 患者の分布(予測値)

第3章 疾病背景と概要:全身性エリテマトーデス(SLE)

  • イントロダクション
  • 危険因子
  • 原因
  • 症状
  • 臨床症状
  • 病院
  • 治療および診断で使用される生物学的製剤およびバイオマーカー
  • 診断
  • 分類

第4章 疫学と患者人口

  • 主な調査結果
  • 主要7カ国の全身性エリテマトーデス(SLE)
  • 主要7カ国の全身性エリテマトーデス(SLE)の総有病数
  • 米国
    • 仮定と理論的根拠
    • 全身性エリテマトーデス(SLE)の有病数
    • 全身性エリテマトーデス(SLE)の有病数:性別
    • 全身性エリテマトーデス(SLE)の有病数:年齢別
    • 全身性エリテマトーデス(SLE)の有病数:病型別
  • EU5カ国の全身性エリテマトーデス(SLE)の疫学
    • 仮定と理論的根拠
    • ドイツ
      • 仮定と理論的根拠
      • 全身性エリテマトーデス(SLE)の有病数
      • 全身性エリテマトーデス(SLE)の有病数:性別
      • 全身性エリテマトーデス(SLE)の有病数:年齢別
      • 全身性エリテマトーデス(SLE)の有病数:病型別
    • フランス
    • イタリア
    • スペイン
    • 英国
  • 日本
    • 仮定と理論的根拠
    • 全身性エリテマトーデス(SLE)の有病数
    • 全身性エリテマトーデス(SLE)の有病数:性別
    • 全身性エリテマトーデス(SLE)の有病数:年齢別
    • 全身性エリテマトーデス(SLE)の有病数:病型別

第5章 アンメットニーズ

第6章 市場の成長要因

第7章 市場の障壁

第8章 キーオピニオンリーダーの見解

第9章 付録

  • 調査手法

第10章 DelveInsightのサービス内容

第11章 免責事項

第12章 DelveInsightについて

図表

List of Tables

  • Table 1: Major clinical manifestations of Systemic Lupus Erythematosus (SLE)
  • Table 2: Summary of key pathogenic processes, cells, and molecules in SLE
  • Table 3: Differential Diagnosis of Systemic Lupus Erythematosus
  • Table 4: Diagnostic criteria for Systemic Lupus Erythematosus
  • Table 5: Classification criteria for Systemic Lupus Erythematosus
  • Table 6: Total Diagnosed Prevalent cases of SLE in 7MM (2017-2028)
  • Table 7: Total Diagnosed Prevalent Cases of SLE in the US (2017-2028)
  • Table 8: Gender -Specific Prevalent Cases of SLE in the US (2017-2028)
  • Table 9: Severity Specific Prevalent Cases of SLE in the US (2017-2028)
  • Table 10: Total Diagnosed Prevalent Cases of SLE in Germany (2017-2028)
  • Table 11: Gender Specific Prevalent Cases of SLE in Germany (2017-2028)
  • Table 12: Severity Specific Prevalent Cases of SLE in Germany (2017-2028)
  • Table 13: Total Diagnosed Prevalent Cases of SLE in France (2017-2028)
  • Table 14: Gender Specific Prevalent Cases of SLE in France (2017-2028)
  • Table 15: Severity Specific Prevalent Cases of SLE in France (2017-2028)
  • Table 16: Total Diagnosed Prevalent Cases of SLE in Italy (2017-2028)
  • Table 17: Gender Specific Prevalent Cases of SLE in Italy (2017-2028)
  • Table 18: Severity Specific Prevalent Cases of SLE in Italy (2017-2028)
  • Table 19: Total Diagnosed Prevalent Cases of SLE in Spain (2017-2028)
  • Table 20: Gender Specific Prevalent Cases of SLE in Spain (2017-2028)
  • Table 21: Severity Specific Prevalent Cases of SLE in Spain (2017-2028)
  • Table 22: Total Diagnosed Prevalent Cases of SLE in the UK (2017-2028)
  • Table 23: Gender Specific Prevalent Cases of SLE in the UK (2017-2028)
  • Table 24: Severity Specific Prevalent Cases of SLE in the UK (2017-2028)
  • Table 25: Total Diagnosed Prevalent Cases of SLE in Japan (2017-2028)
  • Table 26: Gender Specific Prevalent Cases of SLE in Japan (2017-2028)
  • Table 27: Severity Specific Prevalent Cases of SLE in Japan (2017-2028)

List of Figures

  • Figure 1: Management of Systemic Lupus Erythematosus
  • Figure 2: Risk Factors of SLE
  • Figure 3: T-cell Signaling and Gene regulation in SLE
  • Figure 4: Role of Innate Cells (Neutrophils, Macrophages, and Dendritic Cells) in SLE
  • Figure 5: Algorithm for the diagnosis of Systemic Lupus Erythematosus
  • Figure 6: Total Diagnosed Prevalent cases of SLE in 7MM (2017-2028)
  • Figure 7: Total Diagnosed Prevalent Cases of SLE in the US (2017-2028)
  • Figure 8: Gender -Specific Cases of SLE in the US (2017-2028)
  • Figure 9: Severity Specific Cases of SLE in the US (2017-2028)
  • Figure 10: Total Diagnosed Prevalent Cases of SLE in Germany (2017-2028)
  • Figure 11: Gender -Specific Cases of SLE in Germany (2017-2028)
  • Figure 12: Severity Specific Cases of SLE in Germany (2017-2028)
  • Figure 13: Total Diagnosed Prevalent Cases of SLE in France (2017-2028)
  • Figure 14: Gender Specific Cases of SLE in France (2017-2028)
  • Figure 15: Severity Specific Cases of SLE in France (2017-2028)
  • Figure 16: Total Diagnosed Prevalent Cases of SLE in Italy (2017-2028)
  • Figure 17: Gender Specific Cases of SLE in Italy (2017-2028)
  • Figure 18: Severity Specific Cases of SLE in Italy (2017-2028)
  • Figure 19: Total Diagnosed Prevalent Cases of SLE in Spain (2017-2028)
  • Figure 20: Gender Specific Cases of SLE in Spain (2017-2028)
  • Figure 21: Severity Specific Cases of SLE in Spain (2017-2028)
  • Figure 22: Total Diagnosed Prevalent Cases of SLE in the UK (2017-2028)
  • Figure 23: Gender Specific Cases of SLE in the UK (2017-2028)
  • Figure 24: Severity Specific Cases of SLE in the UK (2017-2028)
  • Figure 25: Total Diagnosed Prevalent Cases of SLE in Japan (2017-2028)
  • Figure 26: Gender Specific Cases of SLE in Japan (2017-2028)
  • Figure 27: Severity Specific Cases of SLE in Japan (2017-2028)
  • Figure 29: Unmet need: Failure of Numerous clinical trials
  • Figure 30: Unmet Need: Complexity in Pathophysiology of the diseases
  • Figure 31: Steps to fulfill the current unmet need
  • Figure 32: Market Drivers
  • Figure 33:Market Barriers
目次
Product Code: DIEI0226

DelveInsight's 'Systemic Lupus Erythematosus (SLE)-Epidemiology Forecast-2028' report delivers an in-depth understanding of the disease, historical & forecasted epidemiology trends of Systemic Lupus Erythematosus in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2028

Systemic Lupus Erythematosus -Disease Understanding

According to the American College of Rheumatology "Systemic lupus erythematosus, referred to as SLE or lupus, is a chronic (long-term) disease that causes systemic inflammation which affects multiple organs. In addition to affecting the skin and joints, it can affect other organs in the body such as the kidneys, the tissue lining the lungs (pleura), heart (pericardium), and brain." Many patients experience fatigue, weight loss, and fever.

SLE is most commonly seen in women in the reproductive age group (frequently starting at childbearing age), although lupus is increasingly recognized after the age of 40 years, particularly in the Europeans. The disease is prone to relapses and remissions, resulting in considerable morbidity due to flares of disease activity and accumulated organ damage, and an increased risk of premature death, mostly due to infection or cardiovascular disease.

Systemic Lupus Erythematosus -Epidemiology

The Systemic Lupus Erythematosus epidemiology division provides insights about historical and current patient pool and forecasted trends for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (Total Diagnosed Prevalent cases, Gender-Specific Prevalence, and Severity-Specific Prevalence(Mild, Moderate and Severe)) scenario of Systemic Lupus Erythematosus in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2017 to 2028.

According to DelveInsight, the total Diagnosed Prevalent cases of Systemic Lupus Erythematosus (SLE) in the 7MM was found to be 484,213 in 2017. The prevalence of Systemic Lupus Erythematosus in the 7MM is expected to increase during the study period of 2017 to 2028.

Among 7MM, the United States has the highest prevalent population of Systemic Lupus Erythematosus with about 259,474 cases in 2017. Among EU-5 countries, UK had the highest number of prevalent cases with approximately 62,852 cases, followed by Italy in 2017. Germany had the least number of prevalent cases, while in Japan, the diagnosed prevalent population of Systemic Lupus Erythematosus was found to be approximately 58,168.

Systemic Lupus Erythematosus Report Insights

  • The report covers a descriptive overview of the Systemic Lupus Erythematosus, explaining its causes, risk factors, pathophysiology, and diagnosis.
  • Comprehensive insight has been provided into the epidemiology Systemic Lupus Erythematosus in the 7MM countries covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
  • Assesses growth opportunities in 7MM countries with respect to the patient population.

Systemic Lupus Erythematosus Report Key Strengths

  • 10-Year Forecast
  • 7MM Coverage
  • Diagnosed Prevalent Patient Pool of Systemic Lupus Erythematosus
  • Gender-Specific Diagnosed Patient Pool of Systemic Lupus Erythematosus
  • Severity-Specific Diagnosed Patient Pool of Systemic Lupus Erythematosus

Systemic Lupus Erythematosus Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Detailed Pipeline Product Profiles

Key Benefits

  • Key assessments
  • Patient Segmentation
  • Disease Risk & Burden
  • Risk of disease by type

Table of Contents

1. Key Insights

2. Systemic Lupus Erythematosus (SLE): Patient Overview at a Glance

  • 2.1. Total Patient Share (%) Distribution of SLE in 2017
  • 2.2. Total Patient Share (%) Distribution of SLE in 2028

3. Disease Background and Overview: Systemic Lupus Erythematosus (SLE)

  • 3.1. Introduction
  • 3.2. Risk Factors
  • 3.3. Causes
  • 3.4. Symptoms
  • 3.5. Clinical Manifestation
  • 3.6. Pathogenesis
  • 3.7. Biologics and Biomarkers in the Treatment and Diagnosis of SLE
  • 3.8. Diagnosis
    • 3.8.1. Recent classification of SLE

4. Epidemiology and Patient Population

  • 4.1. Key Findings
  • 4.2. Population and Forecast Parameters
  • 4.3. Total Diagnosed Prevalent cases of SLE in 7MM
  • 4.4. United States
    • 4.4.1. Assumptions and Rationale
    • 4.4.2. Total Diagnosed Prevalent cases of SLE in the US
    • 4.4.3. Gender Specific cases of SLE in the US
    • 4.4.4. Severity Specific cases of SLE in the US
  • 4.5. EU5
  • 4.6. Germany
    • 4.6.1. Assumptions and Rationale
    • 4.6.2. Total Diagnosed Prevalent cases of SLE in Germany
    • 4.6.3. Gender Specific cases of SLE in Germany
    • 4.6.4. Severity Specific cases of SLE in Germany
  • 4.7. France
    • 4.7.1. Assumptions and Rationale
    • 4.7.2. Total Diagnosed Prevalent cases of SLE in France
    • 4.7.3. Gender Specific cases of SLE in France
    • 4.7.4. Severity Specific cases of SLE in France
  • 4.8. Italy
    • 4.8.1. Assumptions and Rationale
    • 4.8.2. Total Diagnosed Prevalent cases of SLE in Italy
    • 4.8.3. Gender Specific cases of SLE in Italy
    • 4.8.4. Severity Specific cases of SLE in Italy
  • 4.9. Spain
    • 4.9.1. Assumptions and Rationale
    • 4.9.2. Total Diagnosed Prevalent cases of SLE in Spain
    • 4.9.3. Gender Specific cases of SLE in Spain
    • 4.9.4. Severity Specific cases of SLE in Spain
  • 4.10. United Kingdom
    • 4.10.1. Assumptions and Rationale
    • 4.10.2. Total Diagnosed Prevalent cases of SLE in the UK
    • 4.10.3. Gender Specific cases of SLE in the UK
    • 4.10.4. Severity Specific cases of SLE in the UK
  • 4.11. Japan
    • 4.11.1. Assumptions and Rationale
    • 4.11.2. Total Diagnosed Prevalent cases of SLE in Japan
    • 4.11.3. Gender Specific cases of SLE in Japan
    • 4.11.4. Severity Specific cases of SLE in Japan

5. Unmet Needs

6. Market Drivers

7. Market Barriers

8. KOL Views

9. Appendix

  • 9.1. Report Methodology

10. DelveInsight Capabilities

11. Disclaimer

12. About DelveInsight

Back to Top